New drug combo targets hard-to-treat BRAF cancers in early trial
NCT ID NCT05668585
First seen Nov 21, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This early-phase study tested a new drug called CFT1946, alone or combined with trametinib or cetuximab, in 89 adults with advanced solid tumors that have a BRAF V600 mutation (including melanoma, lung, colon, and thyroid cancers). The main goals were to check safety and find the best dose. Researchers also looked for signs that the tumors shrank or stopped growing. This is not a cure; it aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allina Health System DBA Virginia Piper Cancer Institute
Minneapolis, Minnesota, 55407, United States
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Centre Leon Berard
Lyon, 69008, France
-
Chu de Lille
Lille, 59037, France
-
Community Health Network
Indianapolis, Indiana, 46250, United States
-
Complejo Hospitalario de Jaen
Jaén, 23007, Spain
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
IUCT Oncopole
Toulouse, 31059, France
-
Institut Bergonie
Bordeaux, 33076, France
-
KEM | Evang. Kliniken Essen-Mitte gGmbH
Essen, 45136, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NEXT Oncology Barcelona
Barcelona, 08023, Spain
-
Sarah Cannon and HCA Research Institute
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jiminez Diaz
Madrid, 28040, Spain
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
Universitaetsklinikum Essen
Essen, 45147, Germany
-
University of Arizona - Cancer Center
Tucson, Arizona, 85719, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Virginia Cancer Specialists (NEXT Oncology Virginia)
Fairfax, Virginia, 22031, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.